Hayley Lewis Net Worth

The estimated Net Worth of Hayley Lewis is at least $29.3 Тысяча dollars as of 4 June 2021. Ms Lewis owns over 1,709 units of Zosano Pharma Corp stock worth over $27,876 and over the last 8 years she sold ZSAN stock worth over $1,384.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Lewis ZSAN stock SEC Form 4 insiders trading

Ms has made over 2 trades of the Zosano Pharma Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently she sold 1,709 units of ZSAN stock worth $1,384 on 4 June 2021.

The largest trade she's ever made was buying 4,775 units of Zosano Pharma Corp stock on 19 August 2016 worth over $6,303. On average, Ms trades about 720 units every 194 days since 2016. As of 4 June 2021 she still owns at least 49,779 units of Zosano Pharma Corp stock.

You can see the complete history of Ms Lewis stock trades at the bottom of the page.

Ms. Hayley Lewis biography

Hayley Lewis is the Sr. VP of Operations at Zosano Pharma Corp.

How old is Ms Lewis?

Ms Lewis is 44, she's been the Sr. VP of Operations of Zosano Pharma Corp since . There are 8 older and no younger executives at Zosano Pharma Corp. The oldest executive at Zosano Pharma Corp is Dr. Donald J. Kellerman, 66, who is the VP of Clinical Devel. & Medical Affairs.

What's Ms Lewis's mailing address?

Hayley's mailing address filed with the SEC is C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT, CA, 94555.

Insiders trading at Zosano Pharma Corp

Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L... и Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.

What does Zosano Pharma Corp do?

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.

Complete history of Ms Lewis stock trades at Zosano Pharma Corp

Zosano Pharma Corp executives and stock owners

Zosano Pharma Corp executives and other stock owners filed with the SEC include:

• Steven Lo,
  Sr. VP of Operations, Pres, CEO & Director
• Dr. Donald J. Kellerman,
  VP of Clinical Devel. & Medical Affairs
• Kleanthis Xanthopoulos,
  Independent Director
• Kenneth Greathouse,
  Independent Director
• Steven Elms,
  Independent Director
• Joseph Hagan,
  Director
• Linda Grais,
  Director
• Thorsten von Stein,
  Chief Medical Officer
• Eric Scharin,
  Vice President - Technical Operations
• Dushyant Pathak,
  Senior Vice President - Business Development
• Christine Matthews,
  Chief Financial Officer, Principal Financial Officer
• Steven Lo,
  Chief Executive Officer, Director
• John Walker,
  Chairman of the Board
• Kristina Warga,
  VP & Corp. Controller
• Lu Liu,
  VP of Technical Operations
• Jeffrey L. Quillen,
  Sec.
• Hayley Lewis,
  Sr. VP of Operations
• Christine Matthews,
  Chief Financial Officer
• Capital Iv, Lp Aisling Capi...,
  
• Winnie Wing Kei Tso,
  Chief Financial Officer
• Georgia Erbez,
  Interim CFO
• Konstantinos Alataris,
  President
• M James Barrett,
  Director
• Enterprise Associates 12, L...,
  
• Troy Edward Wilson,
  Director
• Enterprise Associates 12, L...,
  
• Kathy M. Mc Gee,
  Director
• Capital Management, Llc Kaz...,
  
• Gregory David Kitchener,
  Chief Financial Officer
• Elaine Yang,
  Director
• Enterprise Associates 12, L...,
  
• Realty Trust Inc Bio Med Re...,
  
• Laxmi Peri,
  Sr. Vice President, Operations
• Hayley Lewis,
  See Remarks
• Steve Elms,
  Director
• Donald J Kellerman,
  VP, Clinical Dev & Med Affairs